ASCO GI 2023 | Biomarker testing and targeted therapies in colorectal cancer

Jenny Seligmann, MBChB, PhD, University of Leeds, Leeds, UK, discusses the role of biomarker testing in colorectal cancer. Findings from the Phase III FOxTROT trial (NCT00647530) have demonstrated the efficacy of regular testing and neoadjuvant chemotherapy, where pathological response can be surrogate marker for efficacy. Certain targeted therapies can consequently be chosen earlier, and the discovery of novel targets such as HER2, BRAF, and KRAS G12C will give clinicians more treatment options. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

View our new feature exploring genomic biomarkers in metastatic colorectal cancer here: https://bit.ly/3DcSevZ